214698-03-0

Basic information

• Product Name: 7-Amino-1,2,3,4-tetrahydronaphthol
• Synonyms: 7-Amino-1,2,3,4-tetrahydronaphthol;CAS:214698-03-0;7-amino-1,2,3,4-tetrahydro-1-Naphthalenol;7-amino-1,2,3,4-tetrahydronaphthalen-1-ol
• CAS NO: 214698-03-0
• Molecular Formula: C10H13NO
• Molecular Weight: 163.21632
• Mol File: 214698-03-0.mol

Chemical Properties

• Melting Point: 91.7-91.8 °C
• Boiling Point: 346.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.204±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.53±0.20(Predicted)
• CAS DataBase Reference: 7-Amino-1,2,3,4-tetrahydronaphthol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Amino-1,2,3,4-tetrahydronaphthol(214698-03-0)
• EPA Substance Registry System: 7-Amino-1,2,3,4-tetrahydronaphthol(214698-03-0)

Safety Data

• Hazardous Substances Data: 214698-03-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
7-Amino-1,2,3,4-tetrahydronaphthol is utilized as an intermediate in the synthesis of pharmaceutical drugs. Its unique structure allows it to be a key component in the development of new medications, contributing to the advancement of healthcare.
Used in Organic Reactions:
As a reagent in organic reactions, 7-Amino-1,2,3,4-tetrahydronaphthol plays a crucial role in various chemical processes. Its ability to participate in a range of reactions makes it a valuable tool for chemists in the synthesis of complex organic molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 7-Amino-1,2,3,4-tetrahydronaphthol is employed as a building block for the creation of novel organic compounds. Its presence in these reactions can lead to the formation of new molecules with unique properties and potential applications.
Used in Medicinal Chemistry:
7-Amino-1,2,3,4-tetrahydronaphthol is also used in medicinal chemistry, where it may contribute to the discovery of new therapeutic agents. Its potential biological activity is currently a subject of research, with the aim of identifying its pharmacological properties and potential use in treating various diseases.
Used in Research and Development:
Ongoing research into the biological activity of 7-Amino-1,2,3,4-tetrahydronaphthol is conducted in the context of research and development. This exploration is vital for understanding its full potential and unlocking new avenues for its application in medicine and other fields.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 30450-62-5 7-nitro-1,2,3,4-tetrahydro-quinoline 
• 40353-34-2 7-nitro-3,4-dihydro-2H-naphthalen-1-one 
• 32820-11-4 7-nitro-1,2,3,4-tetrahydronaphthalen-1-ol 

Relevant articles and documents

Spirobifluorene-based Porous Organic Polymers as Efficient Porous Supports for Pd and Pt for Selective Hydrogenation

Spirobifluorene-based porous organic polymers (POP) were synthesized following two different protocols; the acetylenic coupling reaction conditions and the Sonogashira cross-coupling reaction. These were utilized as support for the hydrogenation of a series of species containing unsaturated C=C and C=O bonds (4-nitrostyrene, 4-bromobenzophenone, acetophenone, 7-nitro-1-tetralone and 1,2-naphtoquinone confirmed their efficiency). POP1 prepared via a copper-catalysis protocol was completely inactive, while POP2-4 containing residual Pd exhibited different activities in accordance to the accessibility of the substrates to the metal. Further deposition of 0.5 wt% Pd led to active and stable catalysts. They were easily separated by filtration, and after re-dispersion, afforded the same performances for ten successive cycles. This study also evidenced the specific role of the support in these reactions by comparing the behavior of Pd/POP with that of a Pd/C catalyst with the same loading of palladium. The deposition of Pt on these supports led to sub-nanometric particles and, in accordance, to a different catalytic behavior reflected merely by differences in the selectivity.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Imidazole and imidazoline derivatives and uses thereof

This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human α2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where